Business Wire: Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
Business Wire: Galderma Phase III Data Published in the New England Journal of Medicine: Full OLYMPIA 2 Trial Results Demonstrate Nemolizumab’s Rapid Onset of Action in Prurigo Nodularis ...
Galderma Phase III Data Published in the New England Journal of Medicine: Full OLYMPIA 2 Trial Results Demonstrate Nemolizumab’s Rapid Onset of Action in Prurigo Nodularis ...
Medscape: Prurigo Nodularis: Nemolizumab Efficacy Persists at 52 Weeks in Extension Study
Healio: Phase 3 data support nemolizumab for atopic dermatitis, prurigo nodularis treatment
Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by firm, itchy, and often painful bumps (nodules) on the skin. It typically begins with intense itchiness, which can be ...
The New England Journal of Medicine: Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the ...
Morningstar: Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years
Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years
Prurigo nodularis (PN) is a long-lasting skin condition that causes very itchy, hard bumps, often all over the body. The itch can be so intense that people scratch until the skin breaks, leading to ...
Prurigo nodularis (PN) is extremely itchy skin that leads to a bumpy rash. The rash appears as the result of repeated scratching, picking, or rubbing of the itchy areas of the skin. There isn’t one ...